23
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found

      Transcriptional Activation by 1,25-Dihydroxyvitamin D 3 and Synthetic Vitamin D 3 Analogues in Transfected Cultures of Human Keratinocytes

      research-article

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Analogues of vitamin D<sub>3</sub> have recently been introduced for the topical treatment of psoriasis. Their therapeutic effects are thought to be mediated by interaction with the vitamin D<sub>3</sub> receptor (VDR) in epidermal keratinocytes (KCs). The purpose of the present study was to investigate the trans-acting activity of the endogenous VDR in human KCs transfected with a vitamin D response element (VDRE) in response to 1,25-dihydroxÝvitamin D<sub>3</sub> [1,25(OH)<sub>2</sub>D<sub>3</sub>] and the synthetic vitamin D<sub>3</sub> analogues GS 1500, EB 1213, MC 903 (calcipotriol) and KH 1060. Cultured KCs obtained from normal human adults were transfected with a VDRE consisting of a direct repeat (DR) of 2 hexanucleotides separated by 3 nucleotides (AGGTCAaggAGGTCA) cloned as a triple copy into the chloramphenicol acetyltransferase (CAT) reporter plasmid pBLCAT2. This DR3 response element is preferentially activated by heterodimers of the VDR and the retinoid X receptor. Twenty-four hours after transfec-tion, 1,25(OH)<sub>2</sub>D<sub>3</sub>, vitamin D<sub>3</sub> analogues or 9- cis-retinoic acid (9- cis-RA) were added, and, after an additional 24 h, cells were harvested and assayed for CAT activity. 1,25(OH)<sub>2</sub>D<sub>3</sub> dose-dependently induced CAT activity in VDRE-transfected KCs and co-transfection with exogenous human VDR enhanced the response to 1,25(OH)<sub>2</sub>D<sub>3</sub>. Induction of CAT activity by 1,2 5 (OH) <sub>2</sub>D<sub>3</sub> was enhanced in the presence of the endogenous ligand for retinoid X receptor, 9- cis-RA. The synthetic vitamin D<sub>3</sub> analogues dose-dependently stimulated CAT activity. Compared to 1,25(OH)<sub>2</sub>D<sub>3</sub>, KCs were less sensitive to stimulation with MC 903, equally sensitive to EB 1213 and more sensitive to GS 1500 and KH 1060. In conclusion, the endogenous VDR in KCs is responsive to 1,25(OH)<sub>2</sub>D<sub>3</sub> and its synthetic analogues in stimulating gene transcription. To the extent that the biological actions of vitamin D<sub>3</sub> are dependent on its ability to induce gene transcription through the endogenous VDR, this transfection model may be used in the screening of novel vitamin D<sub>3</sub> analogues for biological activity.

          Related collections

          Author and article information

          Journal
          SPP
          Skin Pharmacol Physiol
          10.1159/issn.1660-5527
          Skin Pharmacology and Physiology
          S. Karger AG
          1660-5527
          1660-5535
          1997
          1997
          01 April 2009
          : 10
          : 1
          : 12-20
          Affiliations
          aDepartment of Dermatology, Marselisborg Hospital, and bInstitute of Human Genetics, University of Aarhus, Denmark
          Article
          211455 Skin Pharmacol 1997;10:12–20
          10.1159/000211455
          fed5467d-ba5e-48f5-9337-529b1c9e42ac
          © 1997 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 16 July 1996
          : 04 November 1996
          Page count
          Pages: 9
          Categories
          Original Research Article

          Oncology & Radiotherapy,Pathology,Surgery,Dermatology,Pharmacology & Pharmaceutical medicine
          Vitamin D3 analogues,Human keratinocytes,Vitamin D receptor,Transcriptional activation,Vitamin D3

          Comments

          Comment on this article